DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Dermatomyositis Market Insights, Epidemiology, and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Dermatomyositis, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Dermatomyositis Market
The Dermatomyositis market in the leading markets is expected to grow significantly by 2036.
DelveInsight estimates that the Dermatomyositis market in the 7MM was approximately USD 200 million in 2025 and is expected to expand substantially during the forecast period.
According to DelveInsight estimates, there were nearly 70,000 diagnosed prevalent cases of Dermatomyositis across the 7MM in 2025, with nearly 90% adult and 10% juvenile patients.
The United States accounted for approximately 40,000 diagnosed prevalent cases of Dermatomyositis in 2025, representing the largest patient population among the 7MM.
Among the EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases (~5,000), while Spain reported the lowest (~3,000) in 2025.
In the United States, Interstitial Lung Disease (ILD) was the most common comorbidity associated with Dermatomyositis, affecting approximately 10,000 patients in 2025.
DelveInsight estimates indicate that nearly 70% of US patients had chronic Dermatomyositis, while approximately 30% had the acute form in 2025.
In Japan, approximately 55% of diagnosed patients had mild disease, while nearly 45% had moderate-to-severe disease in 2025.
Leading Dermatomyositis companies, including Priovant Therapeutics/Pfizer, argenx, Pfizer, Galapagos, and others, are actively developing innovative therapies expected to transform the treatment landscape over the forecast period.
Promising Dermatomyositis therapies in clinical development include Brepocitinib, Efgartigimod, Dazukibart (PF-06823859), GLPG3667, Froniglutide, and others.
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/dermatomyositis-market
Key Factors Driving the Dermatomyositis Market
Rising Diagnosis and Disease Awareness
Increasing awareness among physicians, improvements in diagnostic techniques, and better recognition of autoimmune inflammatory myopathies are contributing to earlier diagnosis and expanding the treated patient population.
Growing Adoption of Immunomodulatory Therapies
Current treatment relies heavily on corticosteroids, immunosuppressants, intravenous immunoglobulin (IVIG), and biologics. The approval of OCTAGAM 10% and growing adoption of combination immunomodulatory therapies continue to improve patient outcomes.
Advancements in Targeted Immunotherapy
The development of targeted therapies focusing on TYK2/JAK1 inhibition, FcRn inhibition, and interferon-beta blockade is expected to address major unmet needs in Dermatomyositis management while reducing long-term corticosteroid exposure.
Strong Late-stage Pipeline
Multiple late-stage clinical programs are evaluating novel therapies with differentiated mechanisms of action, creating opportunities for improved disease control, better muscle function, and enhanced quality of life for patients with Dermatomyositis.
Dermatomyositis Competitive Landscape
Current treatment options for Dermatomyositis include corticosteroids, immunosuppressants, intravenous immunoglobulins (IVIG), biologics, and supportive therapies. OCTAGAM 10% (Octapharma) remains the only approved IVIG specifically indicated for adult Dermatomyositis.
Several Dermatomyositis therapies in development include:
Brepocitinib (Priovant Therapeutics/Pfizer)
Efgartigimod (argenx)
Dazukibart (PF-06823859, Pfizer)
GLPG3667 (Galapagos)
Froniglutide
and others.
These investigational therapies target multiple disease pathways including TYK2/JAK1 inhibition, FcRn inhibition, interferon-beta blockade, and other immune-mediated mechanisms, with the goal of improving muscle strength, reducing skin manifestations, minimizing disease progression, and decreasing dependence on long-term corticosteroid therapy.
Discover more about therapies set to grab major Dermatomyositis market share @ Dermatomyositis Treatment Landscape
Recent Developments in the Dermatomyositis Market
In September 2025, Roivant and Priovant Therapeutics announced positive Phase III VALOR study results demonstrating statistically significant and clinically meaningful improvement with Brepocitinib, supporting a planned NDA submission during the first half of 2026.
In June 2025, argenx presented positive Phase II proof-of-concept data for Efgartigimod at EULAR 2025, with the ALKIVIA Phase II/III study demonstrating significant improvements in muscle strength, physical function, and achievement of the primary endpoint.
In January 2025, Pfizer published positive Phase II results for Dazukibart (PF-06823859) in The Lancet, demonstrating significant improvements in cutaneous disease and muscle strength in patients with moderate-to-severe Dermatomyositis. A global Phase III trial is currently ongoing.
What is Dermatomyositis?
Dermatomyositis is a rare autoimmune inflammatory disease characterized by chronic inflammation of the muscles (myositis) and skin (dermatitis). The disease is marked by progressive, symmetrical proximal muscle weakness and distinctive skin manifestations, including heliotrope rash, Gottron’s papules, shawl sign, and photosensitive rashes. Dermatomyositis can affect both adults and children (juvenile dermatomyositis) and is frequently associated with serious complications such as interstitial lung disease (ILD), cardiovascular disease, esophageal dysfunction, and malignancy. Although there is currently no cure, advances in immunomodulatory therapies and targeted biologics are expected to significantly improve disease management and long-term outcomes.
Dermatomyositis Epidemiology Segmentation
The Dermatomyositis epidemiology section provides insights into the historical and current Dermatomyositis patient pool and forecasted trends for the leading markets. The Dermatomyositis market report provides epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Total Diagnosed Prevalent Cases of Dermatomyositis (Juvenile and Adult)
Age-specific Diagnosed Prevalent Cases of Dermatomyositis
Gender-specific Diagnosed Prevalent Cases of Dermatomyositis
Severity-specific Diagnosed Prevalent Cases of Dermatomyositis
Chronicity-specific Diagnosed Prevalent Cases of Dermatomyositis
Comorbidity-specific Diagnosed Prevalent Cases of Dermatomyositis (ILD, Cardiovascular Disease, Cancer Malignancy, Others)
Scope of the Dermatomyositis Market Report
Therapeutic Assessment: Dermatomyositis current marketed and emerging therapies
Dermatomyositis Market Dynamics: Key Market Forecast Assumptions of Emerging Dermatomyositis Drugs and Market Outlook
Key Companies: Priovant Therapeutics/Pfizer, argenx, Pfizer, Galapagos, Octapharma, and others
Key Therapies: Brepocitinib, Efgartigimod, Dazukibart (PF-06823859), GLPG3667, Froniglutide, OCTAGAM 10%, and others
Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies
Unmet Needs, KOL’s Views, Analyst’s Views, Dermatomyositis Market Access and Reimbursement
To know more about Dermatomyositis companies working in the treatment market, visit @ Dermatomyositis Clinical Trials and Therapeutic Assessment
Table of Contents
Dermatomyositis Market Report Introduction
Executive Summary for Dermatomyositis
SWOT Analysis of Dermatomyositis
Dermatomyositis Patient Share (%) Overview at a Glance
Dermatomyositis Market Overview at a Glance
Dermatomyositis Background and Overview
Dermatomyositis Epidemiology and Patient Population
Country-Specific Patient Population of Dermatomyositis
Dermatomyositis Current Treatment and Medical Practices
Dermatomyositis Unmet Needs
Dermatomyositis Emerging Therapies
Dermatomyositis Market Outlook
Country-Wise Dermatomyositis Market Analysis (2022–2036)
Dermatomyositis Market Access and Reimbursement of Therapies
Dermatomyositis Market Drivers
Dermatomyositis Market Barriers
Dermatomyositis Appendix
Dermatomyositis Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
